Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 17/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 17/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029307 | 0.89 | RXRA (0.42) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL20047046 | 0.89 | RXRA (0.41) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL17482381 | 0.89 | CA2 (0.43) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL20047001 | 0.89 | RXRA (0.41) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL20047076 | 0.89 | CA1 (0.43) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL21669973 | 0.88 | RXRA (0.40) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL18818621 | 0.88 | RXRA (0.41) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL22252456 | 0.87 | CA1 (0.49) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL18818594 | 0.86 | RXRA (0.40) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL19276551 | 0.86 | RXRA (0.42) | RXRAGRIN1GRIN2BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3773517-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | Sigilon Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-3687580-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | Sigilon Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |